IMS Disease Insights - Market

IMS Disease Insights
Evidence-based intelligence from the
best informed disease experts
IMS SYNDICATED ANALYTICS
FORECASTING | DISEASE INSIGHTS
Unparalleled insights for intelligent and informed decision-making
IMS has combined its gold standard sales data assets with its
evidence-based epidemiology data to create IMS Disease Insights,
providing the most accurate and unique insights, to allow you to
explore patient and market
dynamics, complemented by CONTENT DETAILS
DISEASE OVERVIEW & BACKGROUND
a patient-validated forecast to
help you understand the future
• Introduction
disease landscape and assist
• Pathology
you in developing a compelling
• Etiology
• Diagnosis and Prognosis
brand strategy.
PATIENT & PHYSICIAN INSIGHTS
MARKET FORECAST & ASSUMPTIONS
Insights
• Key
Epidemiology
• Incidence/Prevalence
• Diagnosed, Undiagnosed
• Treated and Untreated Patients
• Disease Progression/Mortality
• Characteristics
• PatientGender
or Age Demographics
• Patient Co-morbidities
• Overview of Physician Visits
•
Populations
• Drug-Treatable
Treatment
Regimen Trends
• GP and Specialist
Prescription Analysis
• Treatment Dynamics
including
• Dynamic vs Repeat Prescribing
• Key Insights
• 10-year Annualized Forecast
• Base Case Forecast Scenario
• Total Market
• Class-level Market
• Product-level Analysis
• Key Market Drivers
• Forecast Events
• Upside Market Scenario
• Downside Market Scenario
FULLY EVENTED, 10-YEAR ANNUALIZED,
SCENARIO-BASED MARKET FORECAST
MARKET & COMMERCIAL ENVIRONMENT
!
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
• Key Insights
• Market Overview
Market Size: Overall & Class
• Dynamics,
Key Companies
Promotional Spend & Share of
• Voice
Analysis
Key Products: Performance, Brand
• Perceptions,
Unmet Needs
Emerging
Landscape
•
• Life Cycle Management
• Key Investigational Drugs
• Loss of Exclusivity
2
Uncover real answers to your business questions
With unrivalled extensive content, allowing you to fully understand
disease markets to date, patient dynamics and market outlooks,
IMS Disease Insights provides real answers to justify your
business decisions.
Understand how each disease is diagnosed and each patient’s prognosis
• What is the etiology and patho-physiology of this disease?
molecular targets for each disease are being addressed by current therapies, and which are
• What
the key targets for future drugs?
• What is the cost burden associated with this disease?
Gain a complete understanding of the patient population beyond just disease prevalence by
learning from prescriber and patient insights
is the size of the patient population for each disease? What is the prevalence or incidence for this
• What
disease? How will these trends change over time?
proportion of the patient population is diagnosed, and what proportion are treated
• What
pharmacologically?
are the patient co-morbidities for this disease? What are the age and gender demographics?
• What
How do these factors impact treatment choices?
physician types are the primary prescribers for this disease? What proportion of medical visits to
• Which
each medical specialty results in a prescription?
• What are the treatment trends by class or molecule? How have prescription shares shifted over time?
• How do GPs and specialists differ in their prescribing for this disease?
• How much of prescribing is due to dynamic (i.e. switch) vs repeat prescribing?
• How do treatment guidelines and medical practice differ between different countries?
Develop your knowledge base of market dynamics that determine which drugs succeed and
which ones fail in each geography
How have historical sales by volume and value changed for each (molecule, brand, company, or
• therapy
class) in each local market?
Which are the key products for this disease, and how do physicians perceive their performance on
• clinical
endpoints?
How much promotional spend is being invested by major competitors in each local market, and
• which
companies are maximizing their share of voice?
• How will loss of exclusivity events in this market affect the sales dynamics between the key competitors?
What lifecycle management strategies are being employed by the leading companies in this disease
• market,
and which strategies will prove most successful?
Which are the key investigational drugs in this market that will be most disruptive to the market over
• the
next ten years, and what do SWOT analyses say about their potential?
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
3
Confidence through best-in-class forecasting methodology
Using best-in-class methodology, IMS Disease Insights applies
IMS proprietary epidemiology, sales and patient-level data assets to
estimate drug treated populations and current market size, before
projecting forward based on an estimate of the impact of future
events, leading to a patient-level product forecast for the market.
OUR SOURCES OF INFORMATION AND DATA
•
•
•
•
•
IMS MIDAS Sales Data
- by local currency, dollars, and units
IMS MIDAS Prescribing Insights
IMS Disease Analyzer
•
•
•
IMS Promo.Track
IMS Lifecycle:
Patent Focus, R&D Focus, New Product Focus
•
IMS Market Prognosis
IMS Analogue Planner
IMS Oncology Data Assets
(Oncology Analyzer and Enhanced
Tumor Study)
IMS Therapy Prognosis Global
Quantitative and qualitative primary research
is conducted in the local language for each geography, representing >300 surveys and 15 KOLs per
disease. On-the-ground expertise with IMS local affiliates operating in >100 countries is also used.
EXCEL FORECAST REPORTING MODEL
• Price per day of therapy
Historical (4 years) and forecast
• curves
(10 years) for key metrics at
the drug class, brand, segment, and
molecule levels
Measures include treated patients,
• days
of treatment, price/day, sales
(dollars or local currency), by
standard units, market share,
patient share
assumptions by type, date, time
• toKeyimpact,
and impact to specific
brands
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
4
Take advantage of the dynamic and unique forecasting model
DISEASE INSIGHTS FORECAST VALIDATION METHODOLOGY
EPIDEMIOLOGY
AUDIT DATA
Source:
Desk Research
Population
x
Prevalence rate
x
Diagnosed (%)
x
Treatment Rate (%)
Source:
Desk Research
Source:
MIDAS – Sales Data
Standard Units
x
Allocation
÷
Average Daily Dose
Where needed
Source: MIDAS - Simple
Medical Data or MIDAS Detailed Medical Data
Source:
Desk Research
Source: MIDAS – Simple
Medical Data
DAYS OF THERAPY
Source:
Desk Research
Theoretical DOT/patient
x
Compliance:Persistance Rate
÷
Concomitance Adjustment Factor
Source: IMS Disease
Analyzer Primary Market
Research
Source: CoRx from
MIDAS – Detailed
Medical Data
Total Number of Treated Patients
Source: Desk Research
IMS Analogue Planner
Primary Market Research
TREATMENT RATE
AND MARKET SHARE
FUTURE EVENTS
FINAL FORECAST
DISEASE INSIGHTS METHODOLOGY FOR REGIMEN-BASED PATIENT-LEVEL ONCOLOGY FORECASTS
EPIDEMIOLOGY
• Incidence
• Mutation
• Staging
Progression/
Clinical Segmentation
n SYSTEMIC
TREATABLE
EXIT - MORTALITY/
DISCONTINUATION
Treatment duration
% Drug Treated
n SYSTEMIC TREATED
Lines of therapy/
Progression
% Patient Shares
IMS MIDAS
n DRUG TREATED
IMS Patient-Level Data assets
EXIT - MORTALITY/
DISCONTINUATION
IMS Primary Market Research
Price + Dose
Desk Research
$ + VOLUME
(Forecast)
Event Modelling
Primary Market Research
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
$ + VOLUME
(Current market size)
Validation
5
Comprehensive disease-specific reports for 9 individual countries
IMS Disease Insights offers clear, intuitive insights into 18 diseases
in 9 key countries.
DISEASE COVERAGE
•
•
•
•
Central Nervous System Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Neuropathic Pain
•
•
•
•
Oncology
Malignant Melanoma
Prostate Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Breast Cancer
•
•
•
•
•
Cardiovascular & Metabolic Disorders
Type1 and Type 2 Diabetes
Stroke Prevention in Atrial Fibrillation
Dyslipidemia
•
•
•
Immune and Inflammatory
Rheumatoid Arthritis
Psoriasis
Crohn’s Disease
Ulcerative Colitis
Asthma
COPD
•
•
•
•
•
•
GEOGRAPHICAL COVERAGE
•
USA
USA, Japan, China, Brazil, France, Germany,
Italy, Spain, UK
France
Japan
Germany
China
Italy
Spain
Brazil
UK
DELIVERY VIA IMS SYNDICATED ANALYTICS LIBRARY FEATURING:
•
•
•
•
Powerful search functionality
Ability to cut and create your own research report
Export tables, figures and whole chapters into Excel, PowerPoint and Word
Nine language automatic translation including French, German, Chinese, Italian, Spanish, Japanese,
Portuguese, Korean or Russian
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
6
Unmatched epidemiology and patient insights from the best informed disease experts
7 ways that IMS Disease Insights will deliver unique and real value
to your market research
1. Exploitation of all IMS proprietary data assets - sales, medical, promotional
data assetsdata assets at your fingertips
1. and
Allepidemiology
IMS Health proprietary
including
sales, medical,
promotional
and epidemiology
2. Unique
forecasting
methodology,
reconciling
patient anddata
salesassets
forecasts,
taking into account market demand facts and patient dynamics studies
2.
Integration
of extensive
analysis
3. Interactive
forecasting
scenarios
providing 3 forecasts per disease: base,
covering
prescribing,
concomitant
Rx and co-morbidities, based on
upside, downside
primary research of physicians' prescribing trends
4. Integration of extensive analysis of prescribing, concomitant and comorbidity, based on primary research of physicians’ prescribing trends and
3. patient
Epidemiology
journeys and patient insights
providing a complete understanding of the patient population beyond just
5. New share of voice analysis, detailing promotional activity for key players
disease prevalence by learning from prescriber and patient insights
6. Market coverage extended to include emerging countries, China and Brazil,
the five European
countries, the USA, and Japan.
4. complement
Powerful forecasting
methodology
reconciling patient and sales forecasts, taking into account market demand
and patient dynamics as well as the quantitative impact of events
5. Dynamic forecasting model
delivering 3 forecast scenarios per disease: base, upside, downside scenarios
with advanced visualisation capabilities and transparent assumptions
6. Unique share of voice analysis
detailing promotional activity for key players and brand perception analysis
by country
7. Deep research into 9 individual countries
including emerging countries China and Brazil, to complement the five
major European countries, the USA, and Japan
To find out more contact us now for a free demonstration or request a sample table of
contents from Donny Wong, PhD, Director of Disease Insights and Therapy Analysis
at [email protected]
IMS SYNDICATED ANALYTICS | DISEASE INSIGHTS
7
IMS HEALTH
EUROPE & WORLDWIDE
210 Pentonville Road
London N1 9JY
United Kingdom
Tel: +44 (0)20 3075 5888
THE AMERICAS
One IMS Drive
Plymouth Meeting
PA 19462
USA
Tel: +1 610 834-0800
ASIA-PACIFIC
8 Cross Street #21-01/02/03
PWC Building
Singapore 048424
Tel: 65-6227-3006
JAPAN
Toranomon Towers Office 4-1-28
Toranomon, Minato-ku
Tokyo 105-0001
Japan
Tel: 81-3-5425-9000
For all office locations, visit: www.imshealth.com/locations
ABOUT IMS HEALTH
IMS Health is a leading worldwide provider of information, technology and services dedicated to making healthcare
perform better. By applying cutting-edge analytics and proprietary application suites hosted on the IMS One intelligent
cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and
outcomes to enable our clients to run their operations more efficiently. Drawing on information from 100,000 suppliers,
and on insights from more than 40 billion healthcare transactions processed annually, IMS Health’s 9,000+ expert
resources drive results for over 5,000 healthcare clients globally. Customers include pharmaceutical, medical device and
consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and
the financial community. Additional information is available at www.imshealth.com
©2014 IMS Health Incorporated and its affiliates. All rights reserved.
Trademarks are registered in the United States and in various other countries.
DIBRO0314

Download Report